Last week, Roll Call published its list of the most vulnerable U.S. House members in this year’s midterm elections. Listed at #1 — the incumbent lawmaker most likely to lose in November — was Republican Rep. Rob Blum of Iowa.
Reports like this one from the Des Moines Register probably won’t help the congressman’s chances.
A U.S. House ethics committee on Tuesday announced it’s investigating U.S. Rep. Rod Blum, the incumbent Republican in Iowa’s first congressional district, following news reports earlier this year that he failed to disclose his private business on a required form.
The Committee on Ethics for the U.S. House of Representatives said that its top leaders had decided to “extend” a “matter” about Blum.
It’s worth emphasizing that the Ethics Committee didn’t go into any detail about which “matter” it’s investigating, but Blum himself issued a statement on the developments, explaining that the scrutiny is over a “clerical error” about a company he failed to disclose his role in.
At first blush, that may sound like a fairly dull controversy. The truth is far more interesting.
Part of what makes the controversy amazing is the nature of the company in question and its work. The Associated Press reported back in February that Blum was one of two directors who led the Tin Moon Corp., incorporated in May 2016, more than a year into the Iowa Republican’s first term in Congress.
As the AP reported, Tin Moon Corp. offered to “help companies cited for federal food and drug safety violations bury their Food and Drug Administration warning letters below positive internet search results.”
That’s not a great business model for anyone, least of all a sitting member of Congress. But in this case, it gets a little worse.
As we discussed when the story first broke, Blum’s business not only offered to help those accused of violating FDA standards, the Iowan was also featured on the company’s website in a photo featuring his congressional members’ pin. He was, of course, required to disclose his role in the business, but didn’t.









